Sermorelin Wholesale
GHRH Analog Bulk Supply
The original GHRH analog — FDA-approved history, three decades of published research, and the most trusted GH secretagogue in compounding pharmacy practice. Sermorelin (GHRH 1-29 NH₂) stimulates pituitary somatotrophs to produce endogenous GH via the GHRH receptor — preserving the hypothalamic-pituitary axis and natural pulsatile secretion patterns that exogenous GH replacement cannot replicate.
What Is Sermorelin? The Original GHRH Analog Explained
Sermorelin (GHRH 1-29 NH₂) is a synthetic peptide corresponding to the first 29 amino acids of endogenous human growth hormone-releasing hormone (GHRH) — the biologically active N-terminal fragment responsible for pituitary GH stimulation. Unlike exogenous human growth hormone (HGH) which bypasses the hypothalamic-pituitary axis entirely, sermorelin acts upstream at the pituitary GHRH receptor (GHRHR), stimulating somatotroph cells to produce and release endogenous GH through the body’s own regulated secretion system.
Sermorelin was FDA-approved in 1997 as Geref® (Serono Laboratories) — making it the first synthetic GHRH analog to achieve regulatory approval for GH deficiency diagnosis and treatment in children. Geref® was voluntarily withdrawn from the US commercial market in 2008 for business reasons, not safety concerns — and sermorelin continued its clinical life through compounding pharmacy channels, where it became the foundational GH secretagogue for anti-aging and longevity medicine practice through the 2010s and into the current decade.
For wholesale buyers, sermorelin represents the most clinically validated entry point in the GHRH analog category. Its three-decade published research base, FDA approval history, and established compounding pharmacy presence give it institutional credibility that newer GHRH analogs like CJC-1295 cannot match. Competitor listings don’t carry it — making sermorelin a direct market opportunity with consistent demand from compounding pharmacies and longevity clinics.
The Original GHRH Analog
Sermorelin is GHRH(1-29)NH₂ — the N-terminal 29-amino-acid fragment of native GHRH. It was characterized in the 1980s by researchers studying GHRH structure-activity relationships, FDA-approved in 1997, and has accumulated more published human clinical data than any other GHRH analog in the wholesale peptide catalog.
Endogenous GH Stimulation
Sermorelin activates GHRH receptors on pituitary somatotrophs, increasing intracellular cAMP via Gs protein coupling, driving GH gene transcription and pulsatile secretion. Because it stimulates the body’s own GH production pathway — rather than replacing GH exogenously — it preserves the hypothalamic-pituitary axis, somatostatin-mediated feedback, and natural GH pulse patterns.
FDA-Approved Clinical History
Geref® (sermorelin acetate injection) was FDA-approved in 1997 for two indications: GH deficiency diagnosis (GH stimulation test) and treatment of idiopathic GH deficiency in children. This regulatory history provides sermorelin with pharmacokinetic, safety, and efficacy data from FDA clinical trials — a published clinical foundation unavailable for any other GHRH analog in wholesale research supply.
Compounding Pharmacy Staple
Since Geref® market withdrawal in 2008, sermorelin has been continuously supplied through 503A compounding pharmacies for GH optimization protocols. Its 20+ year compounding history, well-established dosing conventions, and physician familiarity make it the standard entry-level GHRH analog for longevity and anti-aging medicine practices starting GH secretagogue programs.
How Sermorelin Works — The GHRH Receptor Pathway
Sermorelin’s mechanism is clean and well-characterized from three decades of published research. It acts exclusively at the pituitary GHRH receptor — a Gs protein-coupled receptor on somatotroph cells — with no direct activity at any other receptor system. This specificity makes sermorelin one of the most precisely targeted peptides in the GH secretagogue wholesale catalog.
Sermorelin → GH Secretion Pathway
The complete signal cascade from sermorelin administration to pulsatile GH release:
A critical research advantage: sermorelin preserves somatostatin-mediated negative feedback. When GH levels rise sufficiently, somatostatin from the hypothalamus inhibits further GH secretion — an autoregulatory mechanism that functions normally with sermorelin but is bypassed with exogenous HGH administration. This preservation of physiological feedback is a central topic in GH axis research and a key reason sermorelin is preferred over HGH in protocols studying natural GH axis dynamics.
Gs/cAMP/PKA Cascade
GHRHR is a Gs-coupled GPCR. Sermorelin binding activates adenylyl cyclase via Gs, increasing intracellular cAMP. Elevated cAMP activates PKA, which phosphorylates CREB transcription factor — driving GH gene transcription and GH synthesis in somatotroph cells.
Preserved Pulsatile Profile
Unlike continuous HGH replacement, sermorelin-stimulated GH follows the body’s natural pulsatile secretion pattern — highest at night during deep sleep, modulated by somatostatin, IGF-1 feedback, and nutritional status. Pulsatile GH research requires this preserved pattern; exogenous HGH cannot replicate it.
Negative Feedback Intact
Somatostatin (SRIF), released from the hypothalamus in response to rising IGF-1 and GH, inhibits GHRHR signaling — keeping GH in physiological range. This autoregulation is absent with exogenous HGH and is a protective pharmacological feature studied extensively in anti-aging research contexts.
Short Half-Life — Natural Kinetics
Sermorelin has a half-life of approximately 10–15 minutes — close to endogenous GHRH. This brief, pulsatile stimulation profile produces discrete GH pulses that best approximate natural hypothalamic-pituitary signaling, making it the preferred compound for research studying native GH axis physiology.
Sermorelin vs CJC-1295 vs Tesamorelin — GHRH Analog Comparison
Sermorelin, CJC-1295 (no DAC), and tesamorelin are the three primary GHRH analogs in wholesale research supply. Understanding their structural and pharmacokinetic differences is critical for research protocol selection and wholesale catalog curation.
| Property | Sermorelin | CJC-1295 No DAC | Tesamorelin |
|---|---|---|---|
| Amino Acids | 29 (native GHRH sequence) | 29 (4 substitutions) | 44 (full GHRH + trans-3-hexenoic acid) |
| Molecular Weight | 3,357.93 Da | 3,367.97 Da | 5,135.74 Da |
| Half-Life | ~10–15 min | ~30 min | ~25–38 min |
| Relative GHRHR Potency | Baseline (1×) | ~49× vs native GHRH | Higher than sermorelin |
| Amino Acid Substitutions | None — native sequence | 4 substitutions (D-Ala², Ala⁸, Ala⁹, Ala¹⁵) | Trans-3-hexenoic acid conjugated |
| FDA Approval History | Yes — Geref® (1997, withdrawn 2008) | No | Yes — Egrifta® (2010, HIV lipodystrophy) |
| Compounding Pharmacy Use | 20+ year history | Common (blend protocols) | Less common |
| Best Research Application | Native GHRH axis research, compounding pharmacy programs | Combination GHRH+GHRP protocols, enhanced potency | Visceral fat/metabolic GHRH research |
| Ipamorelin Stack | ✓ Compatible | ✓ Standard combination | Less common |
Sermorelin’s distinct position: the only GHRH analog in wholesale supply with the native 29-amino-acid sequence (no structural modifications), FDA-approved clinical history, and 20+ years of compounding pharmacy use. For research programs requiring a GHRH analog closest to endogenous GHRH — or for compounding pharmacies with established sermorelin protocols — it is the correct choice.
Sermorelin Wholesale — Full Specifications
Chemical & Molecular Data
| Full Name | Sermorelin (GHRH 1-29 NH₂) |
| Also Known As | GRF(1-29)NH₂, Sermorelin acetate, Geref® (withdrawn) |
| Amino Acids | 29 (native GHRH N-terminal sequence) |
| Molecular Weight | 3,357.93 Da |
| CAS Number | 86168-78-7 |
| Target Receptor | GHRH Receptor (GHRHR) — Gs-coupled |
| Half-life | ~10–15 minutes |
| Physical Form | Lyophilized white powder |
Quality & Purity Standards
| HPLC Purity | ≥98% (batch tested) |
| Identity | Mass spectrometry (MW 3,357.93 Da) |
| Endotoxin | <1 EU/mg (LAL method) |
| Sterility | Sterile-filtered, aseptic fill |
| Water Content | <5% (Karl Fischer) |
| Residual Solvents | ICH Q3C compliant |
| Storage (lyophilized) | -20°C · 24+ months |
| Post-reconstitution | 4°C · use within 28 days |
Sermorelin Wholesale Price — Volume Tiers 2026
Sermorelin is the most affordable GHRH analog per vial in the wholesale catalog — making it accessible for high-volume compounding and research programs while maintaining research-grade quality standards.
| Quantity | Total Price | Per Vial | Per mg | Availability |
|---|---|---|---|---|
| Sermorelin 2mg × 1 | $18 | $18 | $9.00 / mg | ✓ In Stock |
| Sermorelin 2mg × 10CLINIC PACK | $160 | $16 | $8.00 / mg | ✓ In Stock |
| Sermorelin 2mg × 25 | $375 | $15 | $7.50 / mg | ✓ In Stock |
| Sermorelin 2mg × 50 | $700 | $14 | $7.00 / mg | ✓ In Stock |
| Sermorelin 2mg × 100+ | Contact | Custom | Custom rate | ✓ In Stock |
Sermorelin in Published Research — Three Decades of Evidence
FDA Clinical Trials — Geref® Approval Data (1997)
Sermorelin’s FDA approval as Geref® in 1997 required submission of pivotal clinical trial data demonstrating efficacy for GH stimulation testing and treatment of idiopathic GH deficiency in children. Published pharmacokinetic studies from the Geref® program characterized sermorelin’s half-life (~10–15 minutes), GH pulse response, IGF-1 normalization data, and safety profile across pediatric populations — the most extensively characterized clinical dataset of any GHRH analog in wholesale supply.
Geref® FDA approval documents; multiple clinical trial publications 1993–2003
Adult GH Deficiency & Anti-Aging Research
Walker RF (2006, Clinical Interventions in Aging) published a landmark review of sermorelin in adult GH deficiency, examining its role as an alternative to exogenous HGH therapy. The paper established the rationale for sermorelin in adult longevity medicine — specifically the preservation of HPG axis integrity, somatostatin feedback, and pulsatile secretion patterns — that became the foundation for compounding pharmacy sermorelin programs. This paper is widely cited in anti-aging and longevity medicine literature.
Walker RF, Clinical Interventions in Aging, 2006
GHRH Receptor Biology & Pituitary Research
Sermorelin’s role as a selective GHRHR agonist has made it a standard pharmacological tool in pituitary biology research. Published studies have used sermorelin to characterize GHRHR expression patterns, receptor desensitization dynamics, Gs/cAMP/PKA signaling in somatotrophs, and the pituitary response to GHRH across age groups. Its native sequence (no amino acid substitutions) makes it the preferred compound for research requiring the closest approximation to endogenous GHRH signaling.
Extensive publication record in Endocrinology, Journal of Clinical Endocrinology & Metabolism, Neuroendocrinology
GH Axis, Sleep, & Cognitive Research
Published research has studied sermorelin’s effects on sleep architecture (GH secretion is highest during slow-wave sleep; sermorelin enhances this nocturnal GH pulse in published studies), cognitive function in GH-deficient populations, body composition parameters, and bone mineral density. These downstream GH axis effects — all dependent on preserved pulsatile secretion that sermorelin maintains — are active research areas in longevity and aging medicine programs.
Multiple publications in Growth Hormone & IGF Research, Journal of Clinical Endocrinology & Metabolism, 1990s–2020s
Sermorelin Wholesale Quality Standards
Full COA Per Lot
Every batch COA available pre-purchase. HPLC purity, mass spec identity (3,357.93 Da). Lot numbers match vials.
HPLC + Mass Spec
Purity ≥98% by HPLC. Identity confirmed by mass spectrometry every batch.
Endotoxin + Sterility
LAL endotoxin <1 EU/mg. Sterile-filtered, aseptic fill confirmed per batch.
Sequence Integrity
Native 29-AA sequence verified. No unintended substitutions — critical for GHRH native-sequence research.
Cold-Chain Shipping
Ships cold-chain. -20°C stable 24+ months lyophilized. Once reconstituted: 28 days at 4°C.
48h Fulfillment
In-stock orders ship within 48 business hours with cold-chain manifest and tracking.
Who Buys Sermorelin Wholesale
Sermorelin’s compounding pharmacy heritage and FDA-approved history give it the broadest institutional buyer base of any GHRH analog. Not available to the general public.
Compounding Pharmacies
503A pharmacies with established sermorelin compounding programs represent the highest-volume wholesale buyer. 20+ years of compounding use means established protocols, trained staff, and consistent institutional demand.
Longevity & Anti-Aging Clinics
The core prescriber base for sermorelin protocols. Physician-supervised programs using sermorelin as the entry-level GHRH analog for GH optimization research.
Endocrinology Research Programs
Academic endocrinology labs and CROs using sermorelin as a pharmacological GHRH tool in pituitary biology, GH axis, and somatotroph research.
Men’s & Women’s Health Practices
Hormone optimization practices incorporating sermorelin into comprehensive GH, testosterone, and metabolic health research programs.
Regenerative Medicine Clinics
Regenerative practices using sermorelin in tissue repair and recovery research contexts, often alongside BPC-157, TB-500, or NAD+ protocols.
Pediatric & GH Deficiency Research
Research institutions studying GH deficiency mechanisms or pediatric GH axis physiology — sermorelin’s FDA-approved pediatric indication provides the most relevant published clinical reference data.
Sermorelin Wholesale — Frequently Asked Questions
Research Use Only: Sermorelin and all products on this page are sold strictly for in vitro research, laboratory, and licensed compounding use only. Not intended for unsupervised human therapeutic use. Sermorelin was previously FDA-approved as Geref® (withdrawn 2008 for commercial reasons, not safety). Research-grade sermorelin wholesale is not the approved drug product. No claims are made regarding therapeutic efficacy or safety outside of licensed research or compounding contexts. Buyers are solely responsible for compliance with all applicable federal, state, and local laws. By purchasing, you confirm you are a licensed researcher, compounding pharmacist, or qualified institutional buyer acting within the scope of a legitimate program.
Reviews
There are no reviews yet.